Piramal Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,617 Cr +28.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
PP

Piramal Pharma Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Piramal Pharma Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,270Cr
+17.4% YoY
−17.5% QoQ
Net profit
−₹69Cr
Q1 FY26: −₹82 Cr
Margin
8.6%
+3.1 pp YoY
−8.1 pp QoQ

Piramal Pharma Ltd Q1 FY27 key numbers

Revenue
The ADC business is scaling with new acquired capacities (Riverview, Lexington), expecting meaningful revenue growth in single to low double-digit USD million range in coming years.

As stated in Piramal Pharma Ltd's Q1 FY27 earnings call transcript · published 23 Sept 2026. Reported figures, not investment advice.

Price₹211
Market cap₹27.7K Cr

The short version

CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. Piramal Pharma started FY '27 strong with 17% revenue growth and 72% EBITDA growth YoY, signaling positive momentum.

From Piramal Pharma Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Moderate growth
  • CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. (Page 17)
  • Complex hospital generics (CHG) business growth includes both organic and acquisitions (e.g., Canalog), with market share gains in various geographies, particularly ex-US, contributing to growth. The company expects continued positive momentum in CHG in FY27. (Pages 17, 12)
  • Consumer healthcare business expects margin expansion over the next few years, supported by brand momentum, channel expansion, premiumization, and disciplined pricing. (Page 17, 5)

2 more points from Piramal Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Annual capex guidance for FY27 is USD 120 million to USD 135 million; about USD 21 million spent so far (Page 16).
  • Lexington sterile injectable capacity expansion is on track for completion by end of calendar year 2027 (Page 16).
  • Riverview facility expansion completed, adding commercial-scale payload-linker development and manufacturing site with advanced capabilities; less than USD 5 million invested for specific linker payload room (Pages 9 and 15).
  • Combined $90 million expansion program at Riverview and Lexington strengthening integrated ADC platform, including payload-linker manufacturing and sterile fill-finish capabilities (Page 3).

2 more points from Piramal Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Piramal Pharma began FY27 with a stronger opening order book compared to previous periods.
  • The company referenced this stronger opening order book during the last investor call.
  • There may be some ups and downs in order flow between quarters depending on delivery patterns.

2 more points from Piramal Pharma Ltd's call on order book

Create a free account to keep reading this call

What the Q1 FY27 call signalled

2 of 3 strong

RevenueModerate growth
MarginMargins up
CapexCapex planned

Piramal Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Piramal Pharma Ltd Q1 FY27 results — key figures

Piramal Pharma Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue2,2701,934+17.4%2,752-17.5%
Operating profit (EBITDA)195107+82.9%461-57.6%
Operating margin8.6%5.52%+3.1 pp16.74%-8.1 pp
Profit before tax-7-79—43-117.3%
Net profit (PAT)-69-82—-9—
EPS (₹)-0.52-0.61—-0.07—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Piramal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Piramal Pharma Ltd Q1 FY27 results?

CDMO business is expected to drive significant margin expansion, with a target EBITDA margin of 25% by FY30, driven largely by improved utilization at overseas facilities and a differentiated product mix including more innovator products. Piramal Pharma started FY '27 strong with 17% revenue growth and 72% EBITDA growth YoY, signaling positive momentum.

What is Piramal Pharma Ltd share price analysis?

Piramal Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of N/A with a market cap of ₹27,713 Cr. Investors should review the full earnings analysis for detailed insights.

Is Piramal Pharma Ltd planning capital expenditure?

Annual capex guidance for FY27 is USD 120 million to USD 135 million; about USD 21 million spent so far (Page 16).

Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.